Mount Sinai’s High-Resolution Imaging Allows Researchers to Identify How an Aggressive Skin Cancer Metastasizes
Researchers at The Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai collaborated with scientists in Spain to show the mechanisms that cutaneous melanoma, the most aggressive type of skin cancer, activates early on to spark metastasis, according to a study published in Nature. The discovery could lead to early detection of particularly aggressive melanomas, as well as offer a potential target for melanoma treatment.
In this study, an international team led by the Spanish National Cancer Research Centre (CNIO) used a new mouse model, called “MetAlert,” in which mice emit light through bioluminescence when cancer causes a pathogenic activation of lymphatic vessels. Through highly sophisticated high-resolution intravital microscopy carried out at Mount Sinai, researchers detected the mechanisms that melanomas activate very early on to create their own pathways of dissemination, in part through the lymph vessels.
High-resolution intravital microscopy of lymph node metastasis to visualize lymphatic dissemination in real time was performed in The Intravital Core in the Microscopy Core at Mount Sinai led by Javier Bravo-Cordero, PhD, Assistant Professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine. Intravital microscopy is a live and real-time imaging technology that allows researchers to visualize the process of metastasis at the single cell level in affected organs, such as the lymph nodes.
“Intravital imaging technology is opening up new avenues in metastatis research. It allows us to study the process of metastasis at cellular resolution in a living animal,” said Dr. Bravo-Cordero. “These metastasis-visualization techniques are very powerful since they can be adapted to various types of cancer, not only to melanoma, in order to answer fundamental questions in cancer metastasis.”
Mount Sinai’s intravital imaging technology also corroborated CNIO researchers’ finding that a protein called MIDKINE increased the risk of metastasis, making MIDKINE a potential target for therapies and an indicator of how aggressive a patient’s melanoma might be.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.